image
Healthcare - Biotechnology - NASDAQ - US
$ 1.13
-5.22 %
$ 207 M
Market Cap
-1.54
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one QSI stock under the worst case scenario is HIDDEN Compared to the current market price of 1.13 USD, Quantum-Si incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one QSI stock under the base case scenario is HIDDEN Compared to the current market price of 1.13 USD, Quantum-Si incorporated is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one QSI stock under the best case scenario is HIDDEN Compared to the current market price of 1.13 USD, Quantum-Si incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart QSI

image
$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
3.06 M REVENUE
182.62%
-109 M OPERATING INCOME
2.33%
-101 M NET INCOME
-5.26%
-87.8 M OPERATING CASH FLOW
6.64%
-32.7 M INVESTING CASH FLOW
-22.78%
35.9 M FINANCING CASH FLOW
23977.85%
1.19 M REVENUE
51.46%
-30.7 M OPERATING INCOME
-9.22%
-33.1 M NET INCOME
-30.85%
-22.9 M OPERATING CASH FLOW
1.17%
-5.92 M INVESTING CASH FLOW
-100.94%
35.8 M FINANCING CASH FLOW
1789600.00%
Balance Sheet Quantum-Si incorporated
image
Current Assets 218 M
Cash & Short-Term Investments 210 M
Receivables 1.33 M
Other Current Assets 7.07 M
Non-Current Assets 29.9 M
Long-Term Investments 0
PP&E 29.1 M
Other Non-Current Assets 808 K
84.56 %2.85 %11.72 %Total Assets$247.9m
Current Liabilities 18.2 M
Accounts Payable 1.93 M
Short-Term Debt 3.7 M
Other Current Liabilities 12.6 M
Non-Current Liabilities 14.3 M
Long-Term Debt 9.25 M
Other Non-Current Liabilities 5.01 M
5.95 %11.40 %38.70 %28.50 %15.45 %Total Liabilities$32.5m
EFFICIENCY
Earnings Waterfall Quantum-Si incorporated
image
Revenue 3.06 M
Cost Of Revenue 1.46 M
Gross Profit 1.6 M
Operating Expenses 110 M
Operating Income -109 M
Other Expenses -7.57 M
Net Income -101 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)3m(1m)2m(110m)(109m)8m(101m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.32% GROSS MARGIN
52.32%
-3550.56% OPERATING MARGIN
-3550.56%
-3303.04% NET MARGIN
-3303.04%
-46.89% ROE
-46.89%
-40.75% ROA
-40.75%
-46.55% ROIC
-46.55%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Quantum-Si incorporated
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)202020202021202120222022202320232024202420252025
Net Income -101 M
Depreciation & Amortization 4.6 M
Capital Expenditures -4.58 M
Stock-Based Compensation 8.89 M
Change in Working Capital 0
Others -275 K
Free Cash Flow -92.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Quantum-Si incorporated
image
Wall Street analysts predict an average 1-year price target for QSI of $3.65 , with forecasts ranging from a low of $3.65 to a high of $3.65 .
QSI Lowest Price Target Wall Street Target
3.65 USD 223.01%
QSI Average Price Target Wall Street Target
3.65 USD 223.01%
QSI Highest Price Target Wall Street Target
3.65 USD 223.01%
Price
Max Price Target
Min Price Target
Average Price Target
554444333322221111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Quantum-Si incorporated
image
Sold
0-3 MONTHS
57.6 K USD 4
3-6 MONTHS
2.93 M USD 2
6-9 MONTHS
4.04 K USD 1
9-12 MONTHS
9.05 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
235 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™ BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™. businesswire.com - 1 month ago
Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to participate in DNAnexus webinar on large scale proteomics in multi-omics research. businesswire.com - 1 month ago
Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to participate in DNAnexus webinar on large scale proteomics in multi-omics research. businesswire.com - 1 month ago
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). businesswire.com - 1 month ago
Quantum-Si: A Rose, By Any Other Name, Wouldn't Smell As Sweet Quantum-Si aims to revolutionize protein sequencing but faces significant technological and competitive challenges. Commercial reception to Quantum-Si's solutions has been lukewarm so far, suggesting a significant improvement in performance will be needed to drive wider adoption. Quantum-Si believes that it can introduce a superior system in the next few years, but this involves significant uncertainty. seekingalpha.com - 1 month ago
Quantum-Si incorporated (QSI) Q4 2024 Earnings Call Transcript Quantum-Si incorporated (NASDAQ:QSI ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Katherine Atkins - SVP, Commercial Markets Jeff Hawkins - President and CEO Jeff Keyes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Douglas Mcpherson - H.C. Wainright Operator Thank you for standing by. seekingalpha.com - 1 month ago
Quantum-Si Incorporated (QSI) Reports Q4 Loss, Lags Revenue Estimates Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.18 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.16 per share a year ago. zacks.com - 1 month ago
Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results. businesswire.com - 1 month ago
QuantumSi Set to Report Q4 Earnings: Buy, Sell or Hold the Stock? QSI's fourth-quarter performance is expected to have benefited from year-end capital spending and new product launches despite competition and stretched valuation. zacks.com - 2 months ago
Quantum-Si's Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025 BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si's Customers and Researchers to Showcase Next-Generation Protein Sequencing™ at AGBT 2025. businesswire.com - 2 months ago
Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus™ Instrument BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si and IDEX Health & Science to Partner on Optics Module for Proteus™ Instrument. businesswire.com - 3 months ago
Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK. businesswire.com - 3 months ago
8. Profile Summary

Quantum-Si incorporated QSI

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 207 M
Dividend Yield 0.00%
Description Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.
Contact 530 Old Whitfield Street, Guilford, CT, 06437 https://www.quantum-si.com
IPO Date Nov. 13, 2020
Employees 149
Officers Mr. Jeffrey Alan Hawkins President, Chief Executive Officer & Director Dr. Christian Lapointe J.D., Ph.D. General Counsel & Corporate Secretary Dr. Jonathan M. Rothberg Ph.D. Founder & Executive Director Dr. John S. Vieceli Ph.D. Chief Product Officer Mr. Jeffry R. Keyes CPA Chief Financial Officer & Treasurer Mr. Todd C. Bennett Chief Commercial Officer Ms. Lindsay Thompson Chief Human Resources Officer Mr. Todd Rearick Chief Technology Officer Ms. Katherine Atkinson Senior Vice President of Demand Generation & Corporate Brand